Sumatriptan Patent Expiration
Sumatriptan is Used for managing acute migraine episodes. It was first introduced by Glaxosmithkline
Sumatriptan Patents
Given below is the list of patents protecting Sumatriptan, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Imitrex | US5307953 | Single dose dispenser having a piercing member |
Dec 02, 2012
(Expired) | Glaxosmithkline |
| Imitrex |
US5307953 (Pediatric) | Single dose dispenser having a piercing member |
Jun 02, 2013
(Expired) | Glaxosmithkline |
| Imitrex | US5554639 | Medicaments |
Sep 10, 2013
(Expired) | Glaxosmithkline |
| Imitrex |
US5554639 (Pediatric) | Medicaments |
Mar 10, 2014
(Expired) | Glaxosmithkline |
| Tosymra | US10603305 | Formulations comprising triptan compounds | Jun 16, 2030 | Tonix Meds |
| Tosymra | US11337962 | Formulations comprising triptan compounds | Jun 16, 2030 | Tonix Meds |
| Tosymra | US8268791 | Alkylglycoside compositions for drug administration | May 09, 2026 | Tonix Meds |
| Tosymra | US8440631 | Compositions for drug administration | May 09, 2026 | Tonix Meds |
| Tosymra | US9211282 | Formulations comprising triptan compounds | Jul 19, 2031 | Tonix Meds |
| Tosymra | US9283280 | Compositions for drug administration | May 09, 2026 | Tonix Meds |
| Tosymra | US9610280 | Formulations comprising triptan compounds | Jun 16, 2030 | Tonix Meds |
| Tosymra | US9974770 | Formulations comprising triptan compounds | Jun 16, 2030 | Tonix Meds |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Sumatriptan's patents.
Latest Legal Activities on Sumatriptan's Patents
Given below is the list recent legal activities going on the following patents of Sumatriptan.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 14 May, 2024 | US10603305 |
| Change in Power of Attorney (May Include Associate POA) | 07 May, 2024 | US9974770 |
| Email Notification | 07 May, 2024 | US9974770 |
| Change in Power of Attorney (May Include Associate POA) | 25 Apr, 2024 | US11337962 |
| Email Notification | 25 Apr, 2024 | US11337962 |
| Change in Power of Attorney (May Include Associate POA) | 24 Apr, 2024 | US9610280 |
| Email Notification | 24 Apr, 2024 | US10603305 |
| Email Notification | 24 Apr, 2024 | US9610280 |
| Change in Power of Attorney (May Include Associate POA) | 24 Apr, 2024 | US9211282 |
| Change in Power of Attorney (May Include Associate POA) | 24 Apr, 2024 | US10603305 |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Sumatriptan Generics
Several generic applications have been filed for Sumatriptan. The first generic version for Sumatriptan was by Lannett Co Inc and was approved on Feb 19, 2016. And the latest generic version is by Cipla Ltd and was approved on Feb 22, 2021.
Given below is the list of companies who have filed for Sumatriptan generic.
1. CIPLA
Cipla Ltd has filed for 1 generic for Sumatriptan. Given below are the details of the strengths of this generic introduced by Cipla.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 20MG/SPRAY | spray | Prescription | NASAL | AB | Feb 22, 2021 |
2. LANNETT CO INC
Lannett Co Inc has filed for 2 different strengths of generic version for Sumatriptan. Given below are the details of the strengths of this generic introduced by Lannett Co Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5MG/SPRAY | spray | Prescription | NASAL | AB | Feb 19, 2016 |
| 20MG/SPRAY | spray | Prescription | NASAL | AB | Feb 19, 2016 |
3. FLORIDA
Florida Pharmaceutical Products Llc has filed for 1 generic for Sumatriptan. Given below are the details of the strengths of this generic introduced by Florida.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 20MG/SPRAY | spray | Prescription | NASAL | AB | Feb 17, 2021 |
4. PERRIGO UK FINCO
Perrigo Uk Finco Ltd Partnership has filed for 1 generic for Sumatriptan. Given below are the details of the strengths of this generic introduced by Perrigo Uk Finco.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5MG/SPRAY | spray | Prescription | NASAL | AB | Sep 21, 2020 |
5. PADAGIS ISRAEL
Padagis Israel Pharmaceuticals Ltd has filed for 2 different strengths of generic version for Sumatriptan. Given below are the details of the strengths of this generic introduced by Padagis Israel.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5MG/SPRAY | spray | Prescription | NASAL | AB | Sep 21, 2020 |
| 20MG/SPRAY | spray | Prescription | NASAL | AB | Sep 21, 2020 |